On January 25, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that it has made a recording of its January 24, 2019 conference call available on its website (Press release, Anixa Biosciences, JAN 25, 2019, View Source [SID1234532896]). The recording can be found on the Investor Presentation page of the company’s website at www.anixa.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, Dr. Amit Kumar, President and CEO of Anixa, discussed the company’s plans for 2019, including the commercialization path and timeline for CchekTM, its artificial intelligence based cancer diagnostic test, and the clinical path of its CAR-T based ovarian cancer therapeutic program.

Highlights of the call include:

Commercial launch of a CchekTM prostate cancer confirmatory test planned in the third calendar quarter of 2019;
Initial CchekTM launch as a Laboratory Developed Test under CLIA guidelines, while continuing dialogue and process with the US FDA;
Upcoming announcement of CchekTM commercialization partnership with a CLIA certified laboratory;
Investigational New Drug application (IND) filing for ovarian cancer CAR-T therapy expected in the second calendar quarter of 2019; and
Anticipated commencement of human clinical trials of ovarian cancer CAR-T therapy in July 2019.
The recording will be available on the company’s website for 10 days.